| Name | SEP-363856 hydrochloride |
| Description | SEP-363856 hydrochloride (SEP-856 hydrochloride) is an orally active, CNS-active psychotropic agent with a unique non-D2/5-HT2A mechanism of action, demonstrating antipsychotic-like effects and potential for schizophrenia treatment. |
| In vitro | SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor. |
| In vivo | SEP-856 (0.3, 1, and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs. PCP-induced hyperactivity is significantly reduced by SEP-856 (0.3, 1, and 10 mg/kg, orally once). Oral SEP-856 administration (1, 3, and 10 mg/kg) produces a dose-dependent decrease in REM sleep, increase in latency to REM sleep, and increase in cumulative wake (W) time. |
| Storage | 02 | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (250.31 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (22.76 mM), Sonication is recommended.
|
| Keywords | TAAR1 | Serotonin Receptor | SEP-856 Hydrochloride | SEP856 Hydrochloride | SEP-856 | SEP856 | SEP-363856 Hydrochloride | SEP363856 Hydrochloride | SEP-363856 | SEP363856 | SEP 856 Hydrochloride | SEP 856 | SEP 363856 hydrochloride | SEP 363856 | Inhibitor | inhibit | amine-associated receptor 1 (TAAR1) | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT7 Receptor | 5-HT7 | 5-HT2C Receptor | 5-HT2C | 5-HT2A Receptor | 5-HT2A | 5-HT1D Receptor | 5-HT1D | 5-HT1B Receptor | 5-HT1B | 5-HT1A Receptor | 5-HT1A | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Sevoflurane | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | 1,8-Cineole | Dopamine hydrochloride | Cloperastine hydrochloride | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine | Doxepin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
